Galderma

Galderma was formed in 1981 as a joint venture between Nestlé and L'Oréal.[1] Since 2019, it belongs to an investment fund. The company, headed by President & CEO Flemming Ornskow (ex-Shire), has 33 affiliates in 100 countries[2] with a worldwide network of distributors and employs more than 5,000 people. The parent company is based in Lausanne, Switzerland.

The Galderma Code of Ethics[3] lists all applicable legal requirements in the countries where Galderma operates. Galderma S.A. have extensive policies and procedures contained in other supporting documents.[4] talking in terms of environment, social aspects and business ethics..

The origins of Galderma date back to 1961 and the founding of the Owen dermatology company in Dallas, Texas, USA by M. Owen.

In 2007, the Galderma Global Corporate Campaign won the Medical Marketing Association's International Award of Excellence.

In 2010, sales reached 1.2 billion euros, an increase of 16.1% over 2009.

In 2011, Galderma acquired Q-Med, a Swedish medical-device company.[5]

In 2014, Nestlé bought back all the shares from L'Oréal, thus creating a new unit of Nestlé group called Nestle Skin Health. The transaction had a value of €3.1 billion (US$4.23 billion) and was paid for by Nestlé with 21.2 million L'Oréal shares.[6] L'Oréal paid €3.4 billion (US$4.63 billion) for the remaining 27.3 million shares.[6]

In 2019, Nestlé sold Galderma for $10.2 billion to a consortium comprising the EQT VIII fund, Luxinva (a wholly owned subsidiary of Abu Dhabi Investment Authority), PSP Investments and other institutional investors. Since then, it has been the largest dermatology company in the world.

Galderma provides a range of products used to treat acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and skin senescence. Galderma's products sell in more than 70 countries.

The company invests substantially in research and development and sources new treatments from its own activities and from its partnerships with others. It divides its research and development departments between four sites:

• Sophia Antipolis, France. This 25.000-sq. meter center was the company's largest facility. It was closed in 2018.

• Uppsala, Sweden (research and development). This center develops hyaluronic acid-based products which are manufactured using the NASHA technology.
• Princeton New Jersey, USA (clinical development).
• Tokyo Japan (clinical development).

Galderma has manufacturing facilities at the following locations:

• The Alby-sur-Chéran plant in France, inaugurated in 1994, supplies over 70 countries.
• The Baie d'Urfé (Montreal) facility in Canada started production in 2000 and supplies North America.
• The plant in Uppsala, Sweden, manufactures aesthetic and corrective products.
• The Hortolândia site in the state of São Paulo, Brazil serves South America.

The French and Canadian plants have grown in order to improve and increase production capacity. As of 2011 the four sites combined produced over 100 million units.

• List of pharmaceutical companies
• Pharmaceutical industry in Switzerland